List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 Typherix 25 míkróg/0,5 ml, stungulyf, lausn Bóluefni gegn taugaveiki (Vi fjölsykrungur) Typherix 25 mikrogram/0,5 ml, injeksjonsvæske, oppløsning Vaksine mot tyfoidfeber (Vi polysakkarid) Typherix 25 mikrogramai/0,5 ml injekcinis tirpalas užpildytame švirkšte Polisacharidine vakcina nuo viduriu šiltines Typherix 25 mikrogramai/0,5 ml injekcinis tirpalas užpildytame švirkšte Polisacharidinė vakcina nuo vidurių šiltinės Typherix 25 mikrogramai/0,5 ml injekcinis tirpalas užpildytame švirkšte Polisacharidine vakcina nuo viduriu šiltines Typherix 25 mikrogramai/0,5 ml injekcinis tirpalas užpildytame švirkšte Polisacharidine vakcina nuo viduriu šiltines Typherix 25 mikrogrami / 0,5 ml škidums injekcijam pilnšlirce Vi polisaharida vakcina pret vedertifu Vaccinum febris typhoidis polysaccharidicum not available (IS) GLAXOSMITHKLINE PHARMA A/S not available GLAXOSMITHKLINE AS NO not available LT/1/2000/2581/002 GLAXOSMITHKLINE LIETUVA UAB not available LT/1/2000/2581/003 GLAXOSMITHKLINE LIETUVA UAB not available LT/1/2000/2581/004 GLAXOSMITHKLINE LIETUVA UAB not available LT/1/2000/2581/001 GLAXOSMITHKLINE LIETUVA UAB not available GLAXOSMITHKLINE IS LT LT LT LT LV EMA/227889/2018 Page 2/12

3 Typherix 25 Mikrogramm/0,5 ml Injektionslösung Typhus- Polysaccharid-Impfstoff Typherix injektioneste, liuos, esitäytetyssä ruiskussa Polysakkaridirokote lavantautia vastaan Typherix oldat injekcióhoz előretöltött fecskendőben Hastífusz elleni poliszacharid vakcina Typherix solução injetável em seringa pré-cheia Vacina de polissacárido tifoide Typherix solução injetável em seringa pré-cheia Vacina de polissacárido tifoide Typherix solução injetável em seringa pré-cheia Vacina de polissacárido tifoide Typherix solução injetável em seringa pré-cheia Vacina de polissacárido tifoide Typherix, 25 µg/0,5 ml süstelahus süstlis Typherix, injekcní roztok v predplnené injekcní stríkacce Polysacharidová vakcína proti tyfu Typherix, injektioneste, liuos esitäytetyssä ruiskussa Polysakkaridirokote lavantautia vastaan Typherix, injektionsvæske, opløsning UK/H/0289/ GLAXOSMITHKLINE PHARMA GMBH. UK/H/0289/ GLAXOSMITHKLINE not available OGYI-T-8726/01 GLAXOSMITHKLINE KFT. HU UK/H/0289/ SMITH KLINE & FRENCH PORTUGUESA-PDUTOS FARMACEUTICOS LDA UK/H/0289/ SMITH KLINE & FRENCH PORTUGUESA-PDUTOS FARMACEUTICOS LDA UK/H/0289/ SMITH KLINE & FRENCH PORTUGUESA-PDUTOS FARMACEUTICOS LDA UK/H/0289/ SMITH KLINE & FRENCH PORTUGUESA-PDUTOS FARMACEUTICOS LDA not available GLAXOSMITHKLINE not available 59/520/00-C GLAXOSMITHKLINE UK/H/0289/ GLAXOSMITHKLINE UK/H/0289/ GLAXOSMITHKLINE PHARMA A/S AT FI PT PT PT PT EE CZ FI DK EMA/227889/2018 Page 3/12

4 Typherix, injektionsvätska, lösning, förfylld spruta Polysackaridvaccin mot tyfoidfeber Typherix, oplossing voor injectie in een voorgevulde spuit Tyfus polysaccharidevaccin TYPHERIX, Oplossing voor injectie in voorgevulde spuit.polysaccharide Buiktyfusvaccin Typherix, solución inyectable en jeringa precargada Vacuna de polisacárido antitifoideo UK/H/0289/ GLAXOSMITHKLINE AB SE UK/H/0289/001 RVG GLAXOSMITHKLINE B.V. NL UK/H/0289/001 BE GLAXOSMITHKLINE UK/H/0289/ GLAXOSMITHKLINE, S.A. ES not available 5126/2012/01 GLAXOSMITHKLINE not available 5126/2012/03 GLAXOSMITHKLINE not available 5126/2012/04 GLAXOSMITHKLINE not available 5126/2012/05 GLAXOSMITHKLINE not available 5126/2012/06 GLAXOSMITHKLINE not available 5126/2012/07 GLAXOSMITHKLINE not available 5126/2012/08 GLAXOSMITHKLINE BE EMA/227889/2018 Page 4/12

5 Typherix, solution for injection in a pre-filled syringe Typhoid Polysaccharide vaccine Typherix, solution for injection in a pre-filled syringe Typhoid Polysaccharide vaccine Typherix, solution for injection in a pre-filled syringe. Typhoid Polysaccharide vaccine. TYPHERIX, solution injectable dans une seringue preremplie Vaccin typhoidique polysaccharidique TYPHERIX, solution injectable dans une seringue préremplie Vaccin typhoïdique polysaccharidique Typherix, solution injectable en seringue préremplie Vaccin typhoïdique polyosidique not available 5126/2012/02 GLAXOSMITHKLINE UK/H/0289/001 PA 1077/38/1 GLAXOSMITHKLINE (IRELAND) LIMITED not available MA 172/00701 SMITHKLINE BEECHAM PLC MT UK/H/0289/001 PL 10592/0126 SMITHKLINE BEECHAM LTD UK UK/H/0289/001 BE GLAXOSMITHKLINE UK/H/0289/001 BE GLAXOSMITHKLINE UK/H/0289/001 NL24338 LABORATOIRE GLAXOSMITHKLINE UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT IE BE BE FR EMA/227889/2018 Page 5/12

6 Typherix, Injektionslösung in einer Fertigspritze Typhus- Polysaccharid-Impfstoff UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/ GLAXOSMITHKLINE S.P.A. IT UK/H/0289/001 PEI.H GLAXOSMITHKLINE GMBH & CO. KG DE EMA/227889/2018 Page 6/12

7 not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE PT EMA/227889/2018 Page 7/12

8 mikrog/0,5 ml injektioneste, liuos, esitäytetty ruisku Polysakkaridilavantautirokot e. mikrogram/ 0,5 ml injektionsvätska, lösning. Polysackaridvaccin mot tyfoidfeber mikrogram/0,5 ml injektionsvätska, lösning i förfylld spruta polysackaridvaccin mot tyfoidfeber Mikrogramm Injektionslösung in einer Fertigspritze Typhus- Polysaccharid-Impfstoff TYPHIM Vi injekcinis tirpalas Polisacharidinė vakcina nuo vidurių šiltinės Typhim Vi Injektionslösung in einer Fertigspritze Typhim Vi oldatos injekció előretöltött fecskendőben poliszacharid hastífusz vakcina Typhim Vi oldatos injekció előretöltött fecskendőben poliszacharid hastífusz vakcina not available SANOFI PASTEUR EUPE PT not available SANOFI PASTEUR EUPE FI not available SANOFI PASTEUR EUPE SE not available SANOFI PASTEUR EUPE FI not available 521A/91 SANOFI PASTEUR EUPE DE not available LT/1/95/1149/001 SANOFI PASTEUR SA LT not available SANOFI PASTEUR EUPE AT not available OGYI-T-9175/01 SANOFI PASTEUR SA HU not available OGYI-T-9175/02 SANOFI PASTEUR SA HU EMA/227889/2018 Page 8/12

9 TYPHIM Vi Solution for Injection Typhoid Polysaccharide Vaccine TYPHIM Vi Solution for Injection Typhoid Polysaccharide Vaccine TYPHIM Vi Soluzione iniettabile per uso intramuscolare Vaccino antitifico da capsulare Vi TYPHIM Vi Soluzione iniettabile per uso intramuscolare Vaccino antitifico da capsulare Vi Typhim Vi Vi kapsulárna polysacharidová vakcína proti týfusu TYPHIM Vi, 25 microgram/dosis, oplossing voor injectie Polyoside buiktyfusvaccin TYPHIM Vi, 25 microgramm/ dosis, Injektionslösung Typhus-Polysaccharid- Impfstoff TYPHIM Vi, 25 microgramm/ dosis, Injektionslösung Typhus-Polysaccharid- Impfstoff TYPHIM Vi, 25 microgrammes/dose, solution injectable Vaccin typhoïdique polyosidique not available PA 2131/011/001 SANOFI PASTEUR EUPE IE not available PL 46602/0008 SANOFI PASTEUR EUPE UK not available SANOFI PASTEUR EUPE IT not available SANOFI PASTEUR EUPE IT not available 59/0257/96-S SANOFI PASTEUR SA SK not available BE SANOFI PASTEUR EUPE BE not available BE SANOFI PASTEUR EUPE BE not available SANOFI PASTEUR EUPE LU not available BE SANOFI PASTEUR EUPE BE EMA/227889/2018 Page 9/12

10 TYPHIM Vi, 25 microgrammes/dose, solution injectable Vaccin typhoïdique polyosidique Typhim Vi, 25 mikrogram/dose, injeksjonsvæske, oppløsning Vaksine mot tyfoidfeber (polysakkarid) Typhim Vi, 25 mikrogrammi/0,5 ml süstelahus süstlis Kõhutüüfuse polüsahhariidvaktsiin Typhim Vi, 25 míkrógrömm/0,5 ml, stungulyf, lausn. Fjölsykrubóluefni við taugaveiki TYPHIM Vi, injekční roztok v předplněné injekční stříkačce Polysacharidová vakcína proti břišnímu tyfu Typhim Vi, injektionsvæske, opløsning TYPHIM Vi, oplossing voor injectie 0,025 mg/0,5 ml Polyoside buiktyfusvaccin Typhim Vi, otopina za injekciju u napunjenoj štrcaljki, cjepivo protiv tifusa, polisaharidno not available SANOFI PASTEUR EUPE LU not available 8115 SANOFI PASTEUR EUPE NO not available SANOFI PASTEUR SA EE not available SANOFI PASTEUR EUPE IS not available 59/109/01-C SANOFI PASTEUR SA CZ not available SANOFI PASTEUR EUPE DK not available RVG SANOFI PASTEUR EUPE NL not available UP/I /13-02/106 SANOFI PASTEUR SA HR EMA/227889/2018 Page 10/12

11 TYPHIM Vi, roztwór do not available 9523 SANOFI PASTEUR SA PL wstrzykiwań w ampułkostrzykawce Vaccinum febris typhoidis polysaccharidicum Szczepionka przeciw durowi brzusznemu, polisacharydowa TYPHIM Vi, roztwór do not available 9523 SANOFI PASTEUR SA PL wstrzykiwań w ampułkostrzykawce Vaccinum febris typhoidis polysaccharidicum Szczepionka przeciw durowi brzusznemu, polisacharydowa Typhim Vi, šķīdums not available SANOFI PASTEUR SA LV injekcijām pilnšļircē Vēdertīfa polisaharīda vakcīna Vaccinum febris typhoidis polysaccharidicum TYPHIM Vi, solución not available SANOFI PASTEUR EUPE ES inyectable Vacuna antitifoidea de polisacáridos Typhim Vi, solutie injectabila not available 1346/2008/01 SANOFI PASTEUR SA Typhim Vi, solutie injectabila not available 1346/2008/02 SANOFI PASTEUR SA Typhim Vi, solutie injectabila not available 1346/2008/03 SANOFI PASTEUR SA Typhim Vi, solutie injectabila not available 1346/2008/04 SANOFI PASTEUR SA Typhim Vi, solutie injectabila not available 1346/2008/05 SANOFI PASTEUR SA Typhim Vi, solution for not available MA573/00701 SANOFI PASTEUR SA MT injection in a prefilled syringe Polysaccharide typhoid vaccine TYPHIM Vi, solution injectable en multidose Vaccin typhoïdique polyosidique not available NL SANOFI PASTEUR SA FR EMA/227889/2018 Page 11/12

12 TYPHIM Vi, solution injectable en seringue préremplie Vaccin typhoïdique polyosidique ТАЙФИМ Vi Инжекционeн разтвор в предварително напълнена спринцовка Полизахаридна ваксина срещу коремен тиф Тиферикс инжекционен разтвор в предварително напълнена спринцовка Полизахаридна ваксина срещу коремен тиф not available NL SANOFI PASTEUR SA FR not available SANOFI PASTEUR SA BG not available GLAXOSMITHKLINE EOOD BG EMA/227889/2018 Page 12/12

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant

PACKAGE LEAFLET: INFORMATION FOR THE USER. FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant PACKAGE LEAFLET: INFORMATION FOR THE USER FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant Read all of this leaflet carefully before you start using this medicine because

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

V007 B. PACKAGE LEAFLET

V007 B. PACKAGE LEAFLET B. PACKAGE LEAFLET Package leaflet: Information for the user Fyremadel 0.25 mg/0.5 ml solution for injection in pre-filled syringe ganirelix Read all of this leaflet carefully before you start using this

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults Package Leaflet: Information for the User Read all of this leaflet carefully before you

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

PACKAGE LEAFLET: Information for the User

PACKAGE LEAFLET: Information for the User PACKAGE LEAFLET: Information for the User APO-go PEN 10mg/ml Solution for Injection * Apomorphine hydrochloride * Abbreviated to APO-go Pen in the text Read all of this leaflet carefully before you start

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Lidocaine Accord 10 mg/ml solution for injection Lidocaine Accord 20 mg/ml solution for injection Lidocaine hydrochloride Read all of this leaflet carefully before

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride Page 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride Read all of this leaflet carefully before you are given this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate PACKAGE LEAFLET: INFORMATION FOR THE USER Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate Read all of this leaflet carefully before you start using this medicine because it

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

1. WHAT INFLUVAC SUB-UNIT TETRA IS AND WHAT IT IS USED FOR

1. WHAT INFLUVAC SUB-UNIT TETRA IS AND WHAT IT IS USED FOR PACKAGE LEAFLET: INFORMATION FOR THE USER Influvac sub-unit Tetra, suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated) 2018/2019 season This medicine is subject

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you. Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end

More information

Package leaflet: Information for the user. Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package leaflet: Information for the user. Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin Package leaflet: Information for the user, 165 mg/ml, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Module Page 1 of 1

Module Page 1 of 1 Bupivacaine solution for Injection 2.5 mg / ml and 5 mg / ml 1.3 Product information 1.3.1 SPC, labelling and package leaflet 1.3.1.1 Package leaflet Enclosed in subsequent pages, Module 1.3.1 Page 1 of

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/00000883/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER biosyn Arzneimittel GmbH Schorndorfer Strasse 32, 70734 Fellbach, Germany PACKAGE LEAFLET: INFORMATION FOR THE USER Selenase 100 micrograms, solution for injection (50 micrograms/ml) 100 microgram selenium

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September EMA/662335/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): levosalbutamol, salbutamol Procedure No.: PSUSA/00010330/201701 30

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

European Medicines Agency decision

European Medicines Agency decision EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

European Medicines Agency decision

European Medicines Agency decision EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria

More information

European Medicines Agency decision

European Medicines Agency decision EMA/279562/2017 European Medicines Agency decision P/0129/2017 of 8 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing

More information

European Union herbal monograph on Glycine max (L.) Merr., lecithinum

European Union herbal monograph on Glycine max (L.) Merr., lecithinum 31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union

More information

European Union herbal monograph on Ruscus aculeatus L. rhizoma

European Union herbal monograph on Ruscus aculeatus L. rhizoma 30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Symphytum officinale L., radix

European Union herbal monograph on Symphytum officinale L., radix 5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs

More information

(DE/H/1413/001/IB/024 - Response on new day 20 comments) METHOTREXATE DISODIUM 20 MG / 1 ML SOLUTION FOR

(DE/H/1413/001/IB/024 - Response on new day 20 comments) METHOTREXATE DISODIUM 20 MG / 1 ML SOLUTION FOR Sandoz Business use only Page 1 of 2 Package leaflet: information for the patient Ebetrexat 20 mg/ml solution for injection, pre-filled syringe Methotrexate Read all of this leaflet carefully before you

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

B. PACKAGE LEAFLET R001 1

B. PACKAGE LEAFLET R001 1 B. PACKAGE LEAFLET R001 1 Package leaflet: Information for the user Terlipressin acetate 0.12 mg/ml solution for injection terlipressin (as acetate) Read all of this leaflet carefully before you are given

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba 24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion

More information

Package leaflet: Information for the user. {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection

Package leaflet: Information for the user. {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection Package leaflet: Information for the user {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection Pyridoxini hydrochloridum, Thiamini hydrochloridum, Cyanocobalaminum, Lidocaini hydrochloridum

More information

European Medicines Agency decision

European Medicines Agency decision EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)

More information

European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum

European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum 5 June 2018 EMA/HMPC/753041/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum Final Discussion in Working Party

More information

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix 05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working

More information

European Medicines Agency decision

European Medicines Agency decision EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)

More information

European Union herbal monograph on Agrimonia eupatoria L., herba

European Union herbal monograph on Agrimonia eupatoria L., herba 28 January 2015 EMA/HMPC/680597/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Agrimonia eupatoria L., herba Final Discussion in Working Party on European Union monographs

More information

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos 29 September 2015 EMA/HMPC/41108/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos Draft Discussion in Working Party on European

More information

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81 COUNCIL OF THE EUROPEAN UNION Brussels, 7 July 2011 12390/11 LIMITE ENFOPOL 228 DAPIX 81 NOTE From: Presidency To: Law Enforcement Working Party No. prev. doc.: CM 1508/11 Subject: Results of the questionnaire

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)

More information

September 2014 January 2015 March 2015 May 2015 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation

September 2014 January 2015 March 2015 May 2015 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation 7 July 2015 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis Draft

More information

European Union herbal monograph on Hedera helix L., folium

European Union herbal monograph on Hedera helix L., folium 21 November 2017 EMA/HMPC/325716/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hedera helix L., folium Final Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma 21 November 2017 EMA/HMPC/329755/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), Draft Initial assessment Discussion in Working

More information

Patient reporting update

Patient reporting update Patient reporting update François Houÿez Director of Treatment Information & Access, EURORDIS 8 th Pharmacovigilance stakeholders forum EMA, 15/06/2014 15/09/2014 eurordis.org 1 Spontaneous reporting in

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba 28 March 2017 EMA/HMPC/44166/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Melilotus officinalis (L.) Lam., herba Draft Initial assessment Discussion in Working

More information

Package leaflet: Information for the patient. Gadovist 1.0 mmol/ml solution for injection in prefilled syringe. Gadobutrol

Package leaflet: Information for the patient. Gadovist 1.0 mmol/ml solution for injection in prefilled syringe. Gadobutrol Package leaflet: Information for the patient Gadovist 1.0 mmol/ml solution for injection in prefilled syringe Gadobutrol Read all of this leaflet carefully before you are given this medicine because it

More information

European Medicines Agency decision

European Medicines Agency decision EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)

More information